

Contents

10 key OTC deal trends (go to now)	5
A truly transformative year (go to now)	6
Detailed analysis of the 10 key OTC deal trends	
<i>GSK and Pfizer join forces</i> (go to now)	6
<i>Japan's Taisho acquiring UPSA</i> (go to now)	7
<i>Mega deals reshaping the industry</i> (go to now)	10
<i>Pharma firms getting out of OTC</i> (go to now)	11
<i>Pfizer announces strategic review</i> (go to now)	14
<i>Plenty of sellers and buyers</i> (go to now)	15
<i>Nestlé's strategic review for Skin Health</i> (go to now)	16
<i>Mylan's strategic review</i> (go to now)	17
<i>Portfolio streamlining</i> (go to now)	17
<i>Sanofi sells portfolio to Cooper-Vemedia</i> (go to now)	18
<i>Buy-and-build strategies</i> (go to now)	19
<i>Series of acquisitions for Trimb</i> (go to now)	20
<i>Dermapharm on the acquisition trail</i> (go to now)	21
<i>Boosted presence in Germany</i> (go to now)	22
<i>Pure consumer healthcare companies</i> (go to now)	23
<i>Perrigo to focus on consumer healthcare</i> (go to now)	24
<i>Plenty of VMS deals</i> (go to now)	25
<i>Digital technology and e-commerce</i> (go to now)	25
<i>"100% drug-free wearable technology"</i> (go to now)	26
<i>Vision has ambitions in e-commerce</i> (go to now)	27
<i>Interest in microbiome companies</i> (go to now)	28
<i>Not all plain sailing</i> (go to now)	29

Spotlight on key trends (go to now)	31
In-depth look at two OTC deal trends	
<i>VMS category sees batch of big deals</i> (go to now)	31
<i>Private-equity firms stake their claim</i> (go to now)	46
Deal trends in action (go to now)	55
In-depth look at six companies	
<i>GSK and Pfizer to create global leader</i> (go to now)	55
<i>P&G replaces PGT with Merck unit</i> (go to now)	68
<i>Taisho extends its geographic reach</i> (go to now)	75
<i>Prestige focuses on consumer healthcare</i> (go to now)	81
<i>J&J divests Nizoral to three buyers</i> (go to now)	84
<i>Bayer seeks to move on from Merck</i> (go to now)	91
Purchase prices for OTC deals (go to now)	110
Quick guide to purchase prices for OTC deals	